MYCBP2-AS1

Across TCGA pan-cancer cohorts, MYCBP2-AS1 RNA is linked to patient survival in 21 of 34 cancer types, making it the most broadly survival-associated MYCBP2-AS1 data layer.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher MYCBP2-AS1 RNA is associated with better overall survival. In most high-consensus cancer types, elevated MYCBP2-AS1 expression acts as an unfavorable survival marker, although some lineages such as HNSC and PAAD show a favorable association.

HNSC, BLCA, and UVM are the cancer types where MYCBP2-AS1 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Tertile	IV	0.591	0.388	.003	60	view →
BLCA	DFS	Tertile	All	0.543	0.675	.004	46	view →
UVM	DFS	Median	III,IV	0.183	0.824	.001	26	view →
PAAD	DFS	Quartile	All	0.631	0.345	.004	25	view →
LAML	DFS	Median	All	0.475	0.278	.004	20	view →
UCS	DFS	Median	III,IV	0.577	0.265	.005	18	view →
LIHC	DFS	Quartile	III,IV	0.639	0.331	.010	13	view →
BRCA	OS	Quartile	IV	0.523	0.890	.014	6	view →
MESO	OS	Quartile	All	0.720	0.232	.026	6	view →
READ	OS	Tertile	III,IV	0.845	0.564	.019	6	view →
ESCA	OS	Median	III,IV	0.582	0.326	.028	5	view →
KIRP	DFS	Median	All	0.446	0.749	.002	5	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 21 lineages.

MYCBP2-AS1–HNSC (OS)

Open the HNSC breakdown →